Loading...
An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial)
Akram, Perways Ravenscroft, Jane C Rogers, Andy UK Dermatology Clinical Trials Network's HI-Light Vitiligo, Trial Team
Akram, Perways
Ravenscroft, Jane C
Rogers, Andy
UK Dermatology Clinical Trials Network's HI-Light Vitiligo, Trial Team
Abstract
BACKGROUND: Economic evidence for vitiligo treatments is absent., OBJECTIVES: To determine the cost-effectiveness of (i) handheld narrowband ultraviolet B (NB-UVB) and (ii) a combination of topical corticosteroid (TCS) and NB-UVB compared with TCS alone for localized vitiligo., METHODS: Cost-effectiveness analysis alongside a pragmatic, three-arm, placebo-controlled randomized controlled trial with 9 months' treatment. In total 517 adults and children (aged >= 5 years) with active vitiligo affecting = 11 years and the Child Health Utility 9D for those aged 5 to < 18 years. The trial was registered with number ISRCTN17160087 on 8 January 2015., RESULTS: The mean +/- SD cost per participant was 775 +/- 83.7 for NB-UVB, 813 +/- 111.4 for combination treatment and 600 +/- 96.2 for TCS. In analyses adjusted for age and target patch location, the incremental difference in cost for combination treatment compared with TCS was 211 (95% confidence interval 188-235), corresponding to a risk difference of 10.9% (number needed to treat = 9). The incremental cost was 1932 per successful treatment. The incremental difference in cost for NB-UVB compared with TCS was 173 (95% confidence interval 151-196), with a risk difference of 5.2% (number needed to treat = 19). The incremental cost was 3336 per successful treatment., CONCLUSIONS: Combination treatment, compared with TCS alone, has a lower incremental cost per additional successful treatment than NB-UVB only. Combination treatment would be considered cost-effective if decision makers are willing to pay 1932 per additional treatment success. Copyright © 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2021
Type
Article
Collections
Citation
Sach, T.H., Thomas, K.S., Batchelor, J.M., Perways, A., Chalmers, J.R., Haines, R.H., Meakin, G.D., Duley, L., Ravenscroft, J.C., Rogers, A., Santer, M., Tan, W., White, J., Whitton, M.E., Williams, H.C., Cheung, S.T., Hamad, H., Wright, A., Ingram, J.R., Levell, N., Goulding, J.M.R., Makrygeorgou, A., Bewley, A., Ogboli, M., Stainforth, J., Ferguson, A., Laguda, B., Wahie, S., Ellis, R., Azad, J., Rajasekaran, A., Eleftheriadou, V., Montgomery, A.A. and UK Dermatology Clinical Trials Network's HI-Light Vitiligo, Trial Team (2021) 'An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial)', The British journal of dermatology, 184(5), pp. 840-848. doi: https://dx.doi.org/10.1111/bjd.19554.